488 related articles for article (PubMed ID: 19640211)
1. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
2. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
3. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
4. Novel targets for triple-negative breast cancer.
Carey LA
Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
[No Abstract] [Full Text] [Related]
5. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK; Cryns VL; Symmans WF; Sneige N
Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
Venkitaraman R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
[TBL] [Abstract][Full Text] [Related]
7. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative breast cancer: role of the androgen receptor.
Gucalp A; Traina TA
Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
[TBL] [Abstract][Full Text] [Related]
9. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A
Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649
[TBL] [Abstract][Full Text] [Related]
11. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer: a short review.
Elias AD
Am J Clin Oncol; 2010 Dec; 33(6):637-45. PubMed ID: 20023571
[TBL] [Abstract][Full Text] [Related]
13. Beyond triple-negative breast cancer: the need to define new subtypes.
Constantinidou A; Jones RL; Reis-Filho JS
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1197-213. PubMed ID: 20735307
[TBL] [Abstract][Full Text] [Related]
14. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
Voduc D; Nielsen TO
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
16. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features.
Biganzoli E; Coradini D; Ambrogi F; Garibaldi JM; Lisboa P; Soria D; Green AR; Pedriali M; Piantelli M; Querzoli P; Demicheli R; Boracchi P; Nenci I; Ellis IO; Alberti S
Jpn J Clin Oncol; 2011 Feb; 41(2):172-9. PubMed ID: 21199790
[TBL] [Abstract][Full Text] [Related]
17. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
20. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]